Literature DB >> 30418352

Longitudinal pattern of pain medication utilization in peripheral neuropathy patients.

Brian C Callaghan1,2, Evan Reynolds3, Mousumi Banerjee3, Kevin A Kerber1, Lesli E Skolarus1, James F Burke1,2.   

Abstract

We aimed to investigate the pattern and utilization of neuropathic pain medications in peripheral neuropathy patients. Using a privately insured, health care claims database from 2001 to 2014, we identified a retrospective cohort of incident peripheral neuropathy patients (validated ICD-9 definition) after excluding other chronic pain conditions. Outcome measures included opioid prescriptions, chronic opioid therapy (greater than or equal to 90 days of continuous supply), guideline-recommended medications for painful peripheral neuropathy (serotonin reuptake inhibitors, tricyclic antidepressants, and gabapentinoids), and pain specialists (neurologists, physiatrists, and anesthesiologists). Multivariable logistic regression was used to evaluate associations of patient-level factors with these outcomes. The peripheral neuropathy population included 14,426 individuals with a mean (SD) age of 43.1 years (2.8) and 52.4% men followed for 3.1 (1.7) years before and 4.5 (1.4) years after the diagnosis. In this population, 65.9% received ≥1 opioid prescription, and 8.8% received chronic opioid therapy. Of those receiving chronic opioid therapy, only 26.4% received a guideline-recommended medication before chronic opioid status. For guideline-recommended medications, 35.7% received ≥1, 12.4% ≥2, and 3.8% ≥3 different medications. No patient-level factors were associated with both high opioid utilization (initiation and chronic use) and low guideline-recommended medication utilization. Pain specialists were associated with high opioid utilization and high guideline-recommended medication utilization. In conclusion, opioid initiation and transition to chronic opioid therapy are frequent in a peripheral neuropathy population despite few patients receiving more than one guideline-recommended medication. Efforts to decrease opioid utilization and increase guideline-recommended medication use are needed to improve current neuropathic pain treatment.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30418352      PMCID: PMC6377284          DOI: 10.1097/j.pain.0000000000001439

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   7.926


  20 in total

Review 1.  Pharmacologic interventions for painful diabetic neuropathy: An umbrella systematic review and comparative effectiveness network meta-analysis.

Authors:  Marcio L Griebeler; Oscar L Morey-Vargas; Juan P Brito; Apostolos Tsapas; Zhen Wang; Barbara G Carranza Leon; Olivia J Phung; Victor M Montori; M Hassan Murad
Journal:  Ann Intern Med       Date:  2014-11-04       Impact factor: 25.391

Review 2.  Pharmacotherapy for diabetic peripheral neuropathy pain and quality of life: A systematic review.

Authors:  Julie M Waldfogel; Suzanne Amato Nesbit; Sydney M Dy; Ritu Sharma; Allen Zhang; Lisa M Wilson; Wendy L Bennett; Hsin-Chieh Yeh; Yohalakshmi Chelladurai; Dorianne Feldman; Karen A Robinson
Journal:  Neurology       Date:  2017-03-24       Impact factor: 9.910

3.  Opioid use in the management of diabetic peripheral neuropathy (DPN) in a large commercially insured population.

Authors:  Pravinkumar R Patil; Jonathan Wolfe; Qayyim Said; Jeremy Thomas; Bradley C Martin
Journal:  Clin J Pain       Date:  2015-05       Impact factor: 3.442

4.  Impairments and comorbidities of polyneuropathy revealed by population-based analyses.

Authors:  E Matthew Hoffman; Nathan P Staff; Jared M Robb; Jennifer L St Sauver; Peter J Dyck; Christopher J Klein
Journal:  Neurology       Date:  2015-04-01       Impact factor: 9.910

5.  Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.

Authors:  Hude Quan; Vijaya Sundararajan; Patricia Halfon; Andrew Fong; Bernard Burnand; Jean-Christophe Luthi; L Duncan Saunders; Cynthia A Beck; Thomas E Feasby; William A Ghali
Journal:  Med Care       Date:  2005-11       Impact factor: 2.983

6.  Hypertension as a risk factor for diabetic neuropathy: a prospective study.

Authors:  K Y Forrest; R E Maser; G Pambianco; D J Becker; T J Orchard
Journal:  Diabetes       Date:  1997-04       Impact factor: 9.461

7.  Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes.

Authors:  C Daousi; I A MacFarlane; A Woodward; T J Nurmikko; P E Bundred; S J Benbow
Journal:  Diabet Med       Date:  2004-09       Impact factor: 4.359

Review 8.  Distal Symmetric Polyneuropathy: A Review.

Authors:  Brian C Callaghan; Raymond S Price; Eva L Feldman
Journal:  JAMA       Date:  2015-11-24       Impact factor: 56.272

9.  Classification of chronic pain. Descriptions of chronic pain syndromes and definitions of pain terms. Prepared by the International Association for the Study of Pain, Subcommittee on Taxonomy.

Authors: 
Journal:  Pain Suppl       Date:  1986

Review 10.  CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016.

Authors:  Deborah Dowell; Tamara M Haegerich; Roger Chou
Journal:  JAMA       Date:  2016-04-19       Impact factor: 56.272

View more
  4 in total

1.  The hidden costs of painful diabetic neuropathy revealed.

Authors:  A Gordon Smith; Saša Živković
Journal:  Neurol Clin Pract       Date:  2019-10-29

2.  Oxycodone, fentanyl, and morphine amplify established neuropathic pain in male rats.

Authors:  Suzanne M Green-Fulgham; Jayson B Ball; Andrew J Kwilasz; Timothy Fabisiak; Steven F Maier; Linda R Watkins; Peter M Grace
Journal:  Pain       Date:  2019-11       Impact factor: 7.926

3.  Neuropsychological Outcomes in Individuals With Type 1 and Type 2 Diabetes.

Authors:  Nathaniel M Putnam; Evan L Reynolds; Mousumi Banerjee; Kara Mizokami-Stout; Dana Albright; Joyce Lee; Rodica Pop-Busui; Eva L Feldman; Brian C Callaghan
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-04       Impact factor: 5.555

Review 4.  Diabetic neuropathy: what does the future hold?

Authors:  Brian C Callaghan; Gary Gallagher; Vera Fridman; Eva L Feldman
Journal:  Diabetologia       Date:  2020-01-23       Impact factor: 10.122

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.